Vilarem M J, Riou J F, Riou G, Larsen C J
U-301 INSERM, Hôpital, Saint-Louis, Paris, France.
Pathol Biol (Paris). 1987 Nov;35(9):1263-9.
Most experimental data clearly suggest that antitumor agents including DNA intercalative molecules (acridine derivatives, ellipticine and derivatives), or non intercalative ones (epipodophyllotoxines), exert their cytotoxic activity by stabilizing DNA-Topoisomerase II complexes. This phenomenon can be revealed by the presence of DNA breaks upon protein denaturing treatment. In this work, BD-40, an ellipticine analog has been shown to interact in vivo with Topoisomerase II. Moreover, cleavage sites generated by the drug treatment in human proto-oncogene c-myc appear to be mostly localized in the 5' end of the gene locus, which contains regulatory elements. Some of these sites are in a striking correspondence with DNAse I hypersensitive sites, which reportedly reflect the state of activity of genes.
大多数实验数据清楚地表明,包括DNA嵌入分子(吖啶衍生物、玫瑰树碱及其衍生物)或非嵌入分子(表鬼臼毒素)在内的抗肿瘤药物,通过稳定DNA-拓扑异构酶II复合物发挥其细胞毒性活性。这种现象可以通过蛋白质变性处理后DNA断裂的存在来揭示。在这项工作中,玫瑰树碱类似物BD-40已被证明在体内与拓扑异构酶II相互作用。此外,药物处理在人类原癌基因c-myc中产生的切割位点似乎大多位于基因座的5'端,该端含有调控元件。其中一些位点与脱氧核糖核酸酶I超敏位点惊人地对应,据报道,这些超敏位点反映了基因的活性状态。